Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000059075) titled 'Randomized Phase II trial Evaluating the Efficacy of ZolbEtuximab in the second-line for CLaudin18.2 Positive AdvanceD GAstric/EGJ Cancer Patients Previously Treated with Zolbetuximab and Platinum-Based Chemotherapy (ZELDA trial):Translational Biomarker Research (ZELDA-TR trial)' on Oct. 1.
Study Type: Observational
Study Design:
Not selected Not selected
Primary Sponsor: Kyushu Studygroup of Clinical Cancer
Condition:
gastric cancer and esophagogastric junction (EGJ) cancer
Recruitment Status: Not Recruiting
Phase: Not selected
Date of First Enrollment: 2025/10/01
Target Sample Size: 170
Countrie...